Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel Abuse Deterrent Technology
Aug 27, 2014
PALATINE, IL -- (Marketwired) -- 08/27/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant") by the National Institute On Drug Abuse ("NIDA") of the National Institutes of Health to fund Phase I development of Acura's new, early

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on FDA Discussions Surrounding Development of Aversion Hydrocodone With Acetaminophen Tablet
Aug 15, 2014
PALATINE, IL -- (Marketwired) -- 08/15/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today preliminary discussions from a meeting held with the U.S. Food and Drug Administration (FDA) regarding the development pathway for Acura's AVERSION® hydrocodone with acetaminophen tablet

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2014 Financial Results
Aug 04, 2014
PALATINE, IL -- (Marketwired) -- 08/04/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2014 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2014 Financial Results Conference Call on August 5, 2014
Jul 24, 2014
PALATINE, IL -- (Marketwired) -- 07/24/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2014 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug
May 27, 2014
PALATINE, IL -- (Marketwired) -- 05/27/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the US Food and Drug Administration (FDA) advised the Company that the data from our intranasal abuse liability study AP-ADF-301 (Study 301) for our AVERSION hydrocodone bitartrate with

Read more

Summary ToggleAcura Pharmaceuticals Announces Settlement of Patent Litigation With Sandoz Inc.
May 21, 2014
PALATINE, IL -- (Marketwired) -- 05/21/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Sandoz Inc.

Read more

Summary ToggleAcura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
May 08, 2014
PALATINE, IL -- (Marketwired) -- 05/08/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Ranbaxy Inc.

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2014 Financial Results
May 05, 2014
PALATINE, IL -- (Marketwired) -- 05/05/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2014 .

Read more

Summary ToggleAcura Pharmaceuticals to Host First Quarter 2014 Financial Results Conference Call on May 6, 2014
Apr 28, 2014
PALATINE, IL -- (Marketwired) -- 04/28/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the first quarter 2014 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals Announces Return of Product Rights
Apr 10, 2014
PALATINE, IL -- (Marketwired) -- 04/10/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to

Read more

Summary ToggleAcura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Mar 05, 2014
PALATINE, IL -- (Marketwired) -- 03/05/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones , President and Chief Executive Officer, will present at the 26 th Annual

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Mar 03, 2014
PALATINE, IL -- (Marketwired) -- 03/03/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013 .

Read more

Summary ToggleAcura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Feb 18, 2014
PALATINE, IL -- (Marketwired) -- 02/18/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3,

Read more

Summary ToggleAcura Pharmaceuticals Secures $10.0 Million of Debt Financing
Dec 30, 2013
PALATINE, IL -- (Marketwired) -- 12/30/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance LLC , pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of $10.0 million .

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug Development
Dec 09, 2013
PALATINE, IL -- (Marketwired) -- 12/09/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that it met on December 5 th with the U.S. Food and Drug Administration (FDA) to review the results of Acura's Study AP-ADF-301 (Study 301), a phase II clinical study in 40 recreational drug

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2013 Financial Results
Nov 04, 2013
PALATINE, IL -- (Marketwired) -- 11/04/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2013 .

Read more

Summary ToggleAcura Pharmaceuticals Announces Distribution of Nexafed(R) by Rite Aid Pharmacies
Nov 04, 2013
PALATINE, IL -- (Marketwired) -- 11/04/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that NEXAFED [pseudoephedrine hydrochloride (HCl)], its next generation pseudoephedrine with abuse deterrent technology, will now be stocked by Rite Aid Pharmacies.

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2013 Financial Results Conference Call on November 5, 2013
Oct 29, 2013
PALATINE, IL -- (Marketwired) -- 10/29/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter of 2013 following the close of financial markets on

Read more

Displaying 91 - 108 of 160 results